研究者
J-GLOBAL ID:202001016535963908   更新日: 2024年07月17日

吉川 良恵

ヨシカワ ヨシエ | Yoshikawa Yoshie
所属機関・部署:
職名: 講師
競争的資金等の研究課題 (10件):
  • 2021 - 2024 低侵襲でハイスループットな悪性中皮腫の早期診断法の確立
  • 2018 - 2021 多重遺伝子変異導入モデルマウスを用いた悪性中皮腫発症機序解明と治療標的分子の探索
  • 2018 - 2021 悪性中皮腫のゲノム統合解析と合成致死性を利用した分子標的探索の基礎的検討
  • 2016 - 2019 環境癌における3p21領域ゲノム構造異常の詳細解析と癌遺伝子診断への適用
  • 2015 - 2018 日本人悪性中皮腫におけるゲノム不安定性に基づく治療戦略の基礎的検討
全件表示
論文 (25件):
  • Misato Takagi-Kimura, Akio Tada, Takashi Kijima, Shuji Kubo, Masaki Ohmuraya, Yoshie Yoshikawa. BAP1 depletion in human B-lymphoblast cells affects the production of innate immune cytokines and chemokines. Genes to cells : devoted to molecular & cellular mechanisms. 2022
  • Yoshie Yoshikawa, Yusuke Yamada, Mitsuru Emi, Lilit Atanesyan, Jan Smout, Karel de Groot, Suvi Savola, Yukako Nakanishi-Shinkai, Akihiro Kanematsu, Michio Nojima, et al. Risk prediction for metastasis of clear cell renal cell carcinoma using digital multiplex ligation-dependent probe amplification. Cancer science. 2022. 113. 1. 297-307
  • Kouko Hidaka, Tetsushi Takeda, Yoshiaki Kinoshita, Kazuki Nabeshima, Sadafumi Tamiya, Yoshie Yoshikawa, Tohru Tsujimura. Development of mesothelioma in situ and its progression to invasive disease observed in a patient with uncontrolled pleural effusions for 15 years. Pathology international. 2020. 70. 12. 1009-1014
  • Yoshie Yoshikawa, Mitsuru Emi, Takashi Nakano, Giovanni Gaudino. Mesothelioma developing in carriers of inherited genetic mutations. Translational lung cancer research. 2020. 9. Suppl 1. S67-S76
  • Sandra Pastorino, Yoshie Yoshikawa, Harvey I Pass, Mitsuru Emi, Masaki Nasu, Ian Pagano, Yasutaka Takinishi, Ryuji Yamamoto, Michael Minaai, Tomoko Hashimoto-Tamaoki, et al. A Subset of Mesotheliomas With Improved Survival Occurring in Carriers of BAP1 and Other Germline Mutations. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018. JCO2018790352
もっと見る
MISC (1件):
  • Yoshie Yoshikawa, Kozo Kuribayashi, Toshiyuki Minami, Masaki Ohmuraya, Takashi Kijima. Epigenetic Alterations and Biomarkers for Immune Checkpoint Inhibitors-Current Standards and Future Perspectives in Malignant Pleural Mesothelioma Treatment. Frontiers in Oncology. 2020. 10
※ J-GLOBALの研究者情報は、researchmapの登録情報に基づき表示しています。 登録・更新については、こちらをご覧ください。

前のページに戻る